Navigation Links
Allen Kesselring, Ph.D. of EAG Life Sciences Featured in Special Report on Extractables and Leachables
Date:12/13/2012

Maryland Heights, Missouri (PRWEB) December 13, 2012

Allen Kesselring, Ph.D. , Scientific Director of EAG Life Sciences, recently participated in an industry roundtable for a special report on extractables and leachables (E&L) testing, published in the November 2012 issue of Pharmaceutical Technology and featured online at Pharmtech.com. Extractables and leachables continue to challenge the pharmaceutical industry, stirring increasing concerns from manufacturers. E&L investigations focus on potential organic and inorganic impurities released or migrated from packaging components into pharmaceutical products.

In the special report, “Examining the Growing Challenge of Extractables and Leachables”, Dr. Kesselring noted that these studies are most commonly associated with injectables, ophthalmics, and orally inhaled nasal drug products. The routes of drug delivery, length and quantity of exposures make for important considerations in extractable and leachable studies. Dr. Kesselring explains: “The quick and efficient transport of ingredients to the bloodstream, which makes these drug-delivery routes highly effective, also makes them susceptible to impurities arising from the packaging."

In the report, the roundtable experts discussed the changes and advancements in analytical testing for extractables and leachables. Dr. Kesselring explained that while analytical improvements have led to faster, more efficient assessments of E&Ls they have also allowed for increased regulatory expectations. He mentioned recent regulatory initiatives that require more specificity and lower limits of evaluation, such as the forthcoming USP General Chapters 232 and 233 involving elemental impurities and the “published for comment” glass delamination document of 1660.

More published information on extractables and leachables from Dr. Kesselring include:

About Allen Kesselring, Ph.D.
Allen Kesselring, Ph.D. serves as the Scientific Director of EAG Life Sciences. He maintains the scientific excellence, quality and timeliness of the contract research organization’s projects. In this role he serves as technical client liaison regarding GXP compliance. He may be reached for further questions at info.lifesciences@eaglabs.com or 800-659-6059.

About EAG Life Sciences
EAG Life Sciences is a contract laboratory with over 50 years of experience supporting pharmaceutical and medical device companies for their specialized research and development needs. Key services include analytical chemistry, method development and method validation, characterization, extractables and leachables studies, quality control testing and stability services. Clients receive high level of 1:1 technical interaction and responsiveness that is applied to both complex and routine studies. EAG Life Sciences is a division of Evans Analytical Group, global company providing technical services rooted in science. http://www.eaglabs.com.

Read the full story at http://www.prweb.com/releases/Allen/Kesselring/prweb10228986.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Marketing Xocolate International Corporation; Xocai, Announces Their 12-Week Weight Loss Challenge To Make Healthy Changes
2. Xocai Maryland
3. Xocai Massachusetts
4. Studies challenge standards to improve treatment outcomes for patients with clotting disorders
5. Research from ASCOS Quality Care Symposium shows advances and challenges in improving the quality of cancer care
6. Complications challenge rheumatoid arthritis patients after joint replacement surgery
7. Teen Smoking Has Fallen Across Most of U.S.: Report
8. Obese but happy gene challenges the common perception of link between depression and obesity
9. HIV and AIDS prevention--Progress and the challenges ahead
10. People in crowdsourcing challenge find defibrillators in Philadelphia
11. Weill Cornell receives $1.5 million in Grand Challenges Explorations grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for ... Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory ... disorder (ASD) to see films in an environment that accommodates their unique needs. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that ... of CM-AT in children aged 3-8 with Autism, is now enrolling at three new ... children across the United States. , “There are currently no approved drugs that ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017 Research and Markets has ... Strategies - 2016" report to their offering. ... The latest research Fibromyalgia Drugs ... benchmarks in the global Fibromyalgia market. The research answers ... drugs marketed for Fibromyalgia and their clinical attributes? How are they ...
(Date:2/23/2017)... , Feb 23, 2017 Research and ... Analysis & Trends - Industry Forecast to 2025" report to ... ... of around 6.9% over the next decade to reach approximately $47.6 ... market estimates and forecasts for all the given segments on global ...
(Date:2/23/2017)... 2017  MiMedx Group, Inc. (NASDAQ: MDXG), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic, and Dental sectors of healthcare, today announced its ... ended December 31, 2016. Full Year 2016 ... 31% increase over full year 2015 revenue ...
Breaking Medicine Technology: